Neurogenetic Testing Market Trends 2025–2029: Forecasts for Key Growth Segments

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Neurogenetic Testing Market Expected To Expand Between 2025 And 2029?

The neurogenetic testing market size has seen rapid expansion in recent years. It is anticipated to increase from $0.61 billion in 2024 to $0.7 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.5%. This historical development can be ascribed to a greater occurrence of neurological disease cases, an uptick in life science research, a growing prevalence of Parkinson’s disease, more cases of cancer, and heightened awareness among healthcare professionals.

The neurogenetic testing market is poised for significant expansion in the coming years. This market is projected to reach $1.12 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 12.7%. This anticipated growth is driven by several factors, including the expanding uses of personalized medicine, an increase in chronic illnesses, a rise in the number of hospitals and diagnostic laboratories, and the escalating need for early disease identification. Key trends anticipated during this period encompass advancements in technology, increased acceptance of non-invasive testing approaches, the introduction of new products, formation of strategic partnerships, and the identification of new biomarkers for neurological disorders.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Neurogenetic Testing Industry?

The increasing incidence of neurological conditions is projected to boost the expansion of the neurogenetic testing market. These disorders encompass illnesses impacting the nervous system, such as the brain, spinal cord, and nerves. Factors contributing to their widespread occurrence include genetic predispositions, infections, injuries, toxins, autoimmune reactions, and degenerative processes. Neurogenetic testing substantially improves the diagnosis, treatment, and overall management of neurological disorders by providing tailored understanding of genetic risk factors, informing therapeutic choices, and enabling individuals and their families to make well-informed healthcare decisions, ultimately leading to better patient care and results. For example, as reported in April 2022 by the European Brain Council, a non-profit organization based in Belgium, more than 600 neurological diseases and almost 300 psychiatric conditions affect millions worldwide, with 65 million suffering from epilepsy. Within Europe, 10.5 million individuals are living with dementia, a number expected to climb to 18.7 million by 2050. Consequently, the growing occurrence of neurological disorders is anticipated to fuel the expansion of the neurogenetic testing market.

What Are The Primary Types Of Segments Analyzed In The Neurogenetic Testing Market?

The neurogenetic testingmarket covered in this report is segmented –

1) By Type: Microarray Analysis; Whole-Exome Sequencing (WES); Multiplex Ligation Dependent Probe Amplification (MLPA); Polymerase Chain Reaction (PCR) Tests; Other Types

2) By Disease: Rare Genetic Disorder; Cancer; Cystic Fibrosis; Sickle Cell Anemia; Duchenne Muscular Dystrophy; Thalassemia; Huntington’s Disease; Fragile X Syndrome; Other Diseases

3) By End-Users: Hospitals; Specialty Clinics; Research Institutes; Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray; Single Nucleotide Polymorphism (SNP) Microarray; Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing; Clinical Exome Sequencing; Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation; MLPA For Methylation Analysis; MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR); Reverse Transcription PCR (RT-PCR); Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS); Southern Blotting; Fluorescence In Situ Hybridization (FISH); Sanger Sequencing

What Trends Are Expected To Drive The Neurogenetic Testing Market?

Key companies operating within the neurogenetic testing market are developing advanced products, such as whole-genome sequencing, to enhance both the precision and breadth of genetic analysis, thereby enabling more comprehensive and personalized testing for neurological conditions. Whole-genome sequencing (WGS) represents a thorough genetic testing approach that involves mapping the complete DNA sequence of an individual’s entire genome. As an illustration, in March 2024, Nucleus Genomics, a US-based entity specializing in genetic analysis, introduced a new DNA analysis product. This platform seeks to equip individuals with a deeper comprehension of their genetic predispositions, facilitating well-informed decisions concerning their health and overall well-being. With its cutting-edge technology and expert genetic counseling offerings, Nucleus Genomics is set to redefine the scope of genetic testing, making the power of whole-genome sequencing directly accessible to individuals and fundamentally changing the field of genomic medicine.

Who Are The Top Performing Companies In The Neurogenetic Testing Market In Recent Years?

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Neurogenetic Testing Market?

North America was the largest region in the neurogenetic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Neurogenetic Testing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=16131&type=smp

Browse Through More Reports Similar to the Global Neurogenetic Testing Market 2025, By The Business Research Company

Genetic Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

Epigenetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/epigenetics-global-market-report

Optogenetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/optogenetics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795